HC Wainwright Downgrades MiNK Therapeutics (NASDAQ:INKT) to Neutral

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) was downgraded by equities researchers at HC Wainwright from a "strong-buy" rating to a "neutral" rating in a note issued to investors on Tuesday, Marketbeat reports. They currently have a $35.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 72.33% from the company's current price.

Separately, William Blair downgraded shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Friday, July 11th.

MiNK Therapeutics Price Performance

NASDAQ INKT traded down $2.94 during trading hours on Tuesday, hitting $20.31. 677,478 shares of the company's stock traded hands, compared to its average volume of 243,007. MiNK Therapeutics has a 52-week low of $4.56 and a 52-week high of $76.00. The company has a market capitalization of $81.04 million, a PE ratio of -8.06 and a beta of 0.19. The firm's 50-day moving average is $10.17 and its 200-day moving average is $9.08.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.09). Equities research analysts predict that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.